폴리비닐클로라이드 해양광생물반응기와 고밀도 폴리에틸렌 해양광생물반응기에서 미세조류, Tetraselmis sp. KCTC12236BP의 생산성 비교

정성균(Seung-Gyun Jung),김수권(Su-Kwon Kim),변문섭(Moon-Sup Bun),조용희(Yonghee Cho),신동우(Dong-Woo Shin),김지훈(Z-Hun Kim),임상민(Sang-Min Lim),이철균(Choul-Gyun Lee) 한국해양바이오학회 2016 한국해양바이오학회지 Vol.8 No.1

It is important to design photobioreactor by cheap material for economical microalgal biomass production. In this study, two types of marine photobioreactors (MPBR), made by either polyvinyl chloride (MPBR-PVC) or high density poly ethylene (MPBR-HDPE), are used and performance of these were compared. Tetraselmis sp. KCTC 12236BP is a green marine alga that isolated from Ganghwa Island, Korea, and the strain was used for marine cultivations using MPBR-PVC and MPBR-HDPE. The cultivations were performed three times in the spring season of 2012 using MPBR-PVC and of 2013 using MPBR-HDPE in the coastal area of Young Heung Island. As the results, MPBR-PVC shows higher biomass productivities than MPBR-HDPE, due to its high light transmittance. In the cultivations using MPBR-PVC, the average sea water temperature was 11.5°C during the first experiment and 16.5°C during the second and third experiments. Average light intensities during three times for experiments were 407.5, 268.1 and 273.0 μ·E·m<SUP>-2</SUP>·s<SUP>-1</SUP>, respectively. The maximum fresh cell weight and average biomass productivity were 1.2 g·L<SUP>-1</SUP> and 0.12 g·L<SUP>-1</SUP>·day<SUP>-1</SUP>. These results showed that Tetraselmis sp. KCTC12236BP were adapted well with the environmental conditions from ocean, and grow in the MPBR-PVC and MPBR-HDPE.

Synthesis of O-(3-[¹⁸F]Fluoropropyl)-L-tyrosine (L-[¹⁸F]FPT) and Its Biological Evaluation in 9L Tumor Bearing Rat

Moon, Byung-Seok,Kim, Sang-Wook,Lee, Tae-Sup,Ahn, Soon-Hyuk,Lee, Kyo-Chul,An, Gwang-Il,Yang, Seung-Dae,Chi, Dae-Yoon,Choi, Chang-Woon,Lim, Sang-Moo,Chun, Kwon-Soo Korean Chemical Society 2005 Bulletin of the Korean Chemical Society Vol.26 No.1

O-(3-[$^{18}$F]Fluoropropyl)-L-tyrosine (L-[$^{18}$F]FPT) was synthesized by nucleophilic radiofluorination followed by acidic hydrolysis of protective groups and evaluated with 9 L tumor bearing rat. L-[$^{18}$F]FPT is an homologue of O-(2-[$^{18}$F]fluoroethyl)-L-tyrosine (L-[$^{18}$F]FET) which recently is studied as a tracer for tumor imaging using positron emission tomography (PET). [$^{18}$F]FPT was directly prepared from the precursor of O-(3-ptoluenesulfonyloxypropyl)- N-(tert-butoxycarbonyl)-L-tyrosine methyl ester. FPT-PET image was obtained at 60 min in 9 L tumor bearing rats. The radiochemical yield of [$^{18}$F]FPT was 0-45% (decay corrected) and the radiochemical purity was more than 95% after HPLC purification. The total time elapsed for the synthesis of [$^{18}$F]FPT was 100 min from EOB (End-of-bombardment). A comparison of uptake studies between [$^{18}$F]FPT and [$^{18}$F]FET was performed. In biodistribution, [$^{18}$F]FPT showed similar pattern with [$^{18}$F]FET in various tissues, but [$^{18}$F]FPT showed low uptake in brain. Furthermore, [$^{18}$F]FPT showed higher tumor-to-brain ratio than [$^{18}$F]FET. In conclusion, [$^{18}$F]FPT seems to be more useful amino acid tracer than [$^{18}$F]FET for brain tumors imaging with PET.

Analysis of keratocystic odontogenic tumor (초)

( Hyoung Sup Lim ),( Su Gwan Kim ),( Seong Yong Moon ),( Ji Su Oh ),( Kyung Nam Moon ),( Jeong Hoon Yoon ) 대한악안면성형재건외과학회 2010 Maxillofacial Plastic Reconstructive Surgery Vol.32 No.2s

심한 협착이 동반된 크론병 환자에서 인플리시맵 치료 후 발생한 소장 천공

임창섭 ( Chang Sup Lim ),문원 ( Won Moon ),박선자 ( Seun Ja Park ),박무인 ( Moo In Park ),김형훈 ( Hyung Hun Kim1 ),김종빈 ( Jong Bin Kim ),최정문 ( Jeong Moon Choi ),장희경 ( Hee Kyung Chang ),이승현 ( Seung Hyun Lee ) 대한소화기학회 2013 대한소화기학회지 Vol.62 No.3

Crohn`s disease is characterized by chronic transmural inflammation of the bowel and is associated with serious complications, such as bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor surgical therapy provides a cure for Crohn`s disease, the primary goals of therapy are to induce and maintain remission and prevent complications. As a biologic agent, infliximab, a monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn`s disease that does not respond to other medical therapies or surgery. Infliximab has proven to be very effective for inducing and maintaining remission in Crohn`s disease; however, infliximab treatment has several potential complications. Here, we report a case of free perforation following a therapeutic response after an initial dose of infliximab for Crohn`s disease. This is the first case report describing a free perforation in a Crohn`s disease patient after an initial dose of infliximab. (Korean J Gastroenterol 2013;62:169-173

크론병 환자에서 아자치오프린 용량 적정은 어떻게 할 것인가? 백혈구 정상 하한치와 내약성에 근거한 최대 용량 적정 방법

임창섭 ( Chang Sup Lim ),문원 ( Won Moon ),박선자 ( Seun Ja Park ),박무인 ( Moo In Park ),최정문 ( Jeong Moon Choi ),유재훈 ( Jae Hoon Yoo ),김종빈 ( Jong Bin Kim ),이준식 ( Jun Sik Lee ) 대한소화기학회 2013 대한소화기학회지 Vol.62 No.2

목적: 일반적으로 크론병 치료에 있어 체중에 근거한 azathioprine (AZA) 사용(2.5 mg/kg/day)이 권고되고 있지만 많은 환자들에서 골수억제 부작용이 나타나고 있다. 이 연구에서는 크론병 환자에서 관해 유지를 위한 AZA의 최대용량을 체중에 근거하지 않고 백혈구의 정상 하한치에 근거해 적정하는 방법에 대해 알아보고자 하였다. 대상 및 방법: 고신대학교 복음병원에서 크론병으로 진단받은후 2010년에서 2011년까지 고신대학교 복음병원에서 추적 관찰하던 78명의 크론병 환자들 중 내약성과 4,000/mm3 이상의 백혈구 수치를 동시에 만족시키면서 스테로이드 없이 관해를 유지하는 AZA 최대용량을 사용하는 환자들을 연구에 포함시켰다. 적정된 최대용량의 AZA 용량과 체중과의 관계에 대해 살펴보았다. 결과: 총 42명의 환자가 연구에 포함되었으며, 그 중 32명이 남자였고 평균 나이는 31세였다. 내약성과 4,000/mm3 이상의 백혈구 수치를 동시에 만족시키면서 스테로이드 없이 관해를 유지하는 AZA 최대용량은 49.1 mg/day였다. 체중당 용량은 0.87 mg/kg/day였고, 체중당 AZA 용량은 체중(γ=?0.51, p=0.01), 체질량지수(γ=?0.33, p=0.034)와 음의 상관관계가 있었다. 40세 이하 군에서의 체중당 AZA의 용량은 40세 이상 군에서보다 의미있게 많았다(p=0.039). 결론: AZA의 용량을 체중에만 근거하여 결정하는 것은 저용량 또는 고용량의 AZA 용량을 초래하여, 결과적으로 부가적인 치료를 필요로 하거나 심각한 부작용을 일으킬 수도 있다. 따라서, 백혈구의 정상 하한치와 내약성에 근거한 최대용량 적정 방법은 AZA 용량 결정에 있어 새롭고 가치있는 방법이다. Background/Aims: Although general guidelines have suggested weight-based dosing of azathioprine (AZA, 2.5 mg/kg/day) for Crohn`s disease (CD), a substantial number of patients develop bone marrow suppression. The aim of this study was to evaluate the maximum dose of AZA not based on weight but titrated according to the lower limit of leukocyte count for maintaining remission in patients with CD. Methods: Among a total of seventy-eight patients with CD, who had been followed-up at Kosin University Gospel Hospital (Busan, Korea) from 2010 to 2011, those treated with the maximum dose of AZA meeting both drug-tolerability and leukocytes count of more than 4,000/mm3 for steroid-free maintaining remission were enrolled. The titrated maximum AZA dose and its relationship with weight were evaluated. Results: A total of 42 patients (male, 32 patients; mean age, 31 years) were enrolled. The maximum dose of AZA was 49.1 mg/day. The dose per weight was 0.87 mg/kg/day and negatively correlated with body weight (γ=?0.51, p=0.01) and BMI (γ=?0.33, p=0.034). AZA dose per weight in the below 40 years old group was significantly higher than that in the above 40 years old group (p=0.039). Conclusions: Dose decision of AZA based only on weight could put the patients to inappropriately low or high dose resulting in need of additional therapy or serious side effect, respectively. Therefore, the maximum dose-titration based on the lower limit of leukocyte count and tolerability is a novel and a valuable strategy in deciding the dose of thiopurines. (Korean J Gastroenterol 2013; 62:111-116)

Immuno-PET Imaging and Radioimmunotherapy of ⁶⁴Cu-/¹⁷⁷Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model

Song, In Ho,Lee, Tae Sup,Park, Yong Serk,Lee, Jin Sook,Lee, Byung Chul,Moon, Byung Seok,An, Gwang Il,Lee, Hae Won,Kim, Kwang Il,Lee, Yong Jin,Kang, Joo Hyun,Lim, Sang Moo Society of Nuclear Medicine 2016 The Journal of nuclear medicine Vol.57 No.7

<P>Immuno-PET provides valuable information about tumor location, phenotype, susceptibility to therapy, and treatment response, especially to targeted radioimmunotherapy. In this study, we prepared antiepidermal growth factor receptor (EGFR) antibody via identical chelator, 3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),1 1,13-trience-3,6,9,-triacetic acid (PCTA), labeled with Cu-64 or Lu-177 to evaluate the EGFR expression levels using immuno-PET and the feasibility of radioimmunotherapy in an esophageal squamous cell carcinoma (ESCC) model. Methods: Cetuximab was conjugated with p-SCN-Bn-PCTA and radiolabeled with Cu-64 or Lu-177. In vitro EGFR expression levels were determined and compared using flow cytometry and cell binding assay. In vivo EGFR expression levels were evaluated via immuno-PET imaging of Cu-64-cetuximab and biodistribution analysis. Micro-SPECT/CT imaging, biodistribution, and radioimmunotherapy studies of Lu-177-cetuximab were performed in the ESCC model. Therapeutic responses were monitored using F-18-FDG PET and immunohistochemical staining. Results: Cu-64- or Lu-177-labeled antibodies showed high radiolabeling yield (>98%), stability (>90%), and favorable immunoreactivity. In vitro EGFR status measured by cell binding assay was correlated with the flow cytometry data. Immuno-PET, micro-SPECT/CT, and biodistribution demonstrated specific uptake in ESCC tumors depending on the EGFR expression levels. Tumor accumulation of Cu-64- and Lu-177-cetuximab was peaked at 48 and 120 h, respectively. Radioimmunotherapy with Lu-177-cetuximab showed significant inliibition of tumor growth (P < 0.01) and marked reduction of F-18-FDG SUV compared with that of control (P < 0.05) Terminal deoxynucleotidyl transferase dUTP nick-end labeling positivity and Ki-67 staining indices increased and decreased, respectively, in the radioimmunotherapy group compared with other groups (P < 0.01). Conclusion: Cu-64-cetuximab immuno-PET represented EGFR expression levels in ESCC tumors, and Lu-177-cetuximab radioimmunotherapy effectively inhibited the tumor growth. The diagnostic and therapeutic convergence radiopharmaceutical Cu-64-/Lu-177-PCTA-cetuximab may be useful as a diagnostic tool in patient selection and a potent radioimmunotherapy agent in EGFR-positive ESCC tumors.</P>

대정맥-심방 우회술로 치료한 기질화된 혈전에 의한 하대정맥 폐쇄 : 증례 보고

문철,임훈,전훈배,염욱,윤익진,이석열,정윤섭 대한혈관외과학회 1999 Vascular Specialist International Vol.15 No.1

Suprarenal IVC obstruction occurs rarely but has various causes. Because this obstruction proceed chronically and usually has collateral circulation, if there is no IVC or hepatic vein obstruction symptom such as Budd-Chiari syndrome, operation is usually needless. However, although symptom is not combined, if malignancy can not be ruled out and there is no proper and radiologically visible collateral, mass resection with IVC wall and bypass graft should be done. 58 year-old female patient visit the hospital for IVC mass that is occasionally discovered by routine abdominal ultrasonography examination. After abdominal CT scanning and IVC venography, IVC obstructive mass between renal vein and hepatic vein was found. Patient didn't show any abnormality in hematological examination such as coagulation and platelet counts. There was no IVC obstruction symptom such as lower limb swelling. Inferior hepatic vein was abnormally dilated and this was regarded as collateral vessel for IVC obstruction. Radiologically, primary leiomyosarcoma was not ruled out and so operation was decided. Suprarenal IVC was dissected and mass was exposed. And with the use of femoral vein and right atrium, temporally veno-veno bypass was performed. Mass including IVC wall was excised and upper end of divided IVC was sutured. Lower end of divided IVC was anastomosed with 16 mm Dacron graft and graft was anastomosed with right atrium by end-to-end methods (Cavoatrial shunt). Postoperative pathologic examination revealed the mass to be organized thrombi. After 2 weeks later, follow-up IVC venography was performed and good patency was found from IVC to right atrium through artificial bypass graft and patient was discharged without complications.

Low Vacuum Generation and Control on BIEN Technology: Mass Flow and Dry Pumping Characteristics

Lim, Jong Yeon,Cheung, Wan Sup,Choi, Yong Moon,Seong, Dae Jin,Shin, Yong Hyeon,Chung, Kwang Hwa Trans Tech Publications, Ltd. 2005 Key engineering materials Vol.277 No.-

<P>Since a clean environment and finite mass flow control on the molecular level are continuously required in current R&D fields and actual process lines, technologies on vacuum generation and control have been playing a significant role in merging a variety of technologies like Bio, Information, Environment, Energy, Space and Nano. Currently, the drive towards dry vacuum pumping has broadly occurred across a spectrum of vacuum applications, from semiconductor manufacture to industrial processing, due to its most visible advantages: it is contamination free. The integrated characteristics evaluation system for dry vacuum pumps has been established in KRISS in collaboration with several branch dry pump suppliers in Korea. The evaluation system exploits a constant volume flow meter to measure mass flow rates real-timely in standard level, and facilitates the evaluation of spatially averaged sound power levels using a semi-anechoic chamber. New and overhauled roots, claw, classical screw, and scroll type pumps supplied from the manufacturers have been evaluated using the evaluation system in terms of ultimate pressure, pumping speed, vibration, and sound power. We selected the mass flow measuring method with a constant chamber volume of 875 L because of its direct monitoring capability which does not allow blind mass flow rate measurements, and proved that the method allows us to measure five decades of mass flow rates from 1×10-2 to 1×103 mbar-l/s with a measurement uncertainty of ±3%, which is within the internationally accepted standards limit. In this work, we demonstrate how the integrated pump characteristics evaluation and mass flow control method have been significant in the low vacuum range of 10-4 to 103 mbar.</P>

여우주머니의 배양세포중의 간세포 보호활성

문영심,임운섭,이미경,김영중,허훈 서울대학교 1995 藥學論文集 Vol.20 No.-

Method for the Synthesis of Amine-Functionalized Fullerenes Involving SET-Promoted Photoaddition Reactions of α-Silylamines

Lim, Suk Hyun,Yi, Jinju,Moon, Gyeong Min,Ra, Choon Sup,Nahm, Keepyung,Cho, Dae Won,Kim, Kyungmok,Hyung, Tae Gyung,Yoon, Ung Chan,Lee, Ga Ye,Kim, Soojin,Kim, Jinheung,Mariano, Patrick S. American Chemical Society 2014 Journal of organic chemistry Vol.79 No.15

<P>A novel method for the preparation of structurally diverse fullerene derivatives, which relies on the use of single electron transfer (SET)-promoted photochemical reactions between fullerene C<SUB>60</SUB> and α-trimethylsilylamines, has been developed. Photoirradiation of 10% EtOH–toluene solutions containing C<SUB>60</SUB> and α-silylamines leads to high-yielding, regioselective formation of 1,2-adducts that arise through a pathway in which sequential SET-desilylation occurs to generate α-amino and C<SUB>60</SUB> anion radical pair intermediates, which undergo C–C bond formation. Protonation of generated α-aminofullerene anions gives rise to formation of monoaddition products that possess functionalized α-aminomethyl-substituted 1,2-dihydrofullerene structures. Observations made in this effort show that the use of EtOH in the solvent mixture is critical for efficient photoproduct formation. In contrast to typical thermal and photochemical strategies devised previously for the preparation of fullerene derivatives, the new photochemical approach takes place under mild conditions and does not require the use of excess amounts of substrates. Thus, the method developed in this study could broaden the scope of fullerene chemistry by providing a simple photochemical strategy for large-scale preparation of highly substituted fullerene derivatives. Finally, the α-aminomethyl-substituted 1,2-dihydrofullerene photoadducts are observed to undergo photoinduced fragmentation reactions to produce C<SUB>60</SUB> and the corresponding <I>N</I>-methylamines.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/joceah/2014/joceah.2014.79.issue-15/jo501034t/production/images/medium/jo-2014-01034t_0012.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/jo501034t'>ACS Electronic Supporting Info</A></P>